Scenarios that move ABBV
AbbVie Inc. Common Stock
Scenarios that move ABBV: 12 analyses, 4 positive, 8 negative.
- · Opus Genetics receives FDA approval for presbyopia eye drop — ▼ · impact -25 · confidence high · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -17 · confidence medium · horizon weeks
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▼ · impact -28 · confidence medium · horizon weeks
- · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -10 · confidence low · horizon quarters
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▲ · impact +58 · confidence high · horizon immediate
- · Liquidia stock plunges 57% after UTHR patent setback — ▲ · impact +10 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -25 · confidence low · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▲ · impact +26 · confidence medium · horizon weeks
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -42 · confidence medium · horizon quarters
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▼ · impact -25 · confidence high · horizon quarters
- · Xenon files epilepsy NDA as depression study setback weighs — ▲ · impact +15 · confidence low · horizon weeks
- · Definium reports second Phase III success in anxiety program — ▼ · impact -40 · confidence low · horizon quarters